Comprehensive analysis of the FOXA1-related ceRNA network and identification of the MAGI2-AS3/DUSP2 axis as a prognostic biomarker in prostate cancer

Background Prostate cancer (PCa) is the second most common cause of cancer-related deaths in American men. Even though increasing evidence has disclosed the competitive endogenous RNA (ceRNA) regulatory networks among cancers, the complexity and behavior characteristics of the ceRNA network in PCa remain unclear. Our study aimed to investigate the forkhead box A1 (FOXA1)-related ceRNA regulatory network and ascertain potential prognostic markers associated with PCa. Methods RNA sequence profiles downloaded from The Cancer Genome Atlas (TCGA) were analyzed to recognize differentially expressed genes (DEGs) derived from tumor and non-tumor adjacent samples as well as FOXA1low and FOXA1high tumor samples. The enrichment analysis was conducted for the dysregulated mRNAs. The network for the differentially expressed long non-coding RNA (lncRNA)-associated ceRNAs was then established. Survival analysis and univariate Cox regression analysis were executed to determine independent prognostic RNAs associated with PCa. The correlation between DUSP2 and immune cell infiltration level was analyzed. Tissue and blood samples were collected to verify our network. Molecular experiments were performed to explore whether DUSP2 is involved in the development of PCa. Results A ceRNA network related to FOXA1 was constructed and comprised 18 lncRNAs, 5 miRNAs, and 44 mRNAs. The MAGI2-AS3~has-mir-106a/has-mir-204~DUSP2 ceRNA regulatory network relevant to the prognosis of PCa was obtained by analysis. We markedly distinguished the MAGI2-AS3/DUSP2 axis in the ceRNA. It will most likely become a clinical prognostic model and impact the changes in the tumor immune microenvironment of PCa. The abnormal MAGI2-AS3 expression level from the patients’ blood manifested that it would be a novel potential diagnostic biomarker for PCa. Moreover, down-expressed DUSP2 suppressed the proliferation and migration of PCa cells. Conclusions Our findings provide pivotal clues to understanding the role of the FOXA1-concerned ceRNA network in PCa. Simultaneously, this MAGI2-AS3/DUSP2 axis might be a new significant prognostic factor associated with the diagnosis and prognosis of PCa.

[1]  Hongbing Shen,et al.  Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma , 2022, Journal of Hematology & Oncology.

[2]  Hui Zhang,et al.  Long noncoding RNA LINC00958 suppresses apoptosis and radiosensitivity of colorectal cancer through targeting miR-422a , 2021, Cancer cell international.

[3]  Jinghui Zhang.  Abstract IA-18: Big pediatric cancer genomic data: Discovery, precision medicine, and data sharing , 2021 .

[4]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[5]  Yushui Ma,et al.  Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma , 2021, Molecular therapy. Nucleic acids.

[6]  N. Palanisamy,et al.  Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression , 2020, Nature Communications.

[7]  Yue-Ming Li,et al.  Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers , 2020, Frontiers in Oncology.

[8]  R. Veitia,et al.  Forkhead Transcription Factors in Health and Disease. , 2020, Trends in Genetics.

[9]  Shuzhen Liu,et al.  Identification of the 3-lncRNA Signature as a Prognostic Biomarker for Colorectal Cancer , 2020, International journal of molecular sciences.

[10]  A. Dmitriev,et al.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms , 2020, International journal of molecular sciences.

[11]  Fenghua Wang,et al.  The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors , 2020, Molecular cancer.

[12]  Lulu Sun,et al.  Long noncoding RNA SNHG4 promotes renal cell carcinoma tumorigenesis and invasion by acting as ceRNA to sponge miR-204-5p and upregulate RUNX2 , 2020, Cancer cell international.

[13]  Yingying Gao,et al.  Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM , 2020, British journal of cancer.

[14]  M. Lupien,et al.  Pioneer of prostate cancer: past, present and the future of FOXA1 , 2020, Protein & cell.

[15]  Hui Yang,et al.  Analyzing the lncRNA, miRNA, and mRNA-associated ceRNA networks to reveal potential prognostic biomarkers for glioblastoma multiforme , 2020, Cancer Cell International.

[16]  Zhi Zhou,et al.  Long noncoding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-149-5p and regulating FOXM1 expression , 2020, Cancer Cell International.

[17]  Chunli Lin,et al.  Circular RNA ITCH suppresses proliferation, invasion, and glycolysis of ovarian cancer cells by up-regulating CDH1 via sponging miR-106a , 2020, Cancer Cell International.

[18]  Y. Tao,et al.  miRNA-based biomarkers, therapies, and resistance in Cancer , 2020, International journal of biological sciences.

[19]  Yun Xiao,et al.  Dissecting the Functional Mechanisms of Somatic Copy-Number Alterations Based on Dysregulated ceRNA Networks across Cancers , 2020, Molecular therapy. Nucleic acids.

[20]  Suzie K. Hight,et al.  An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis , 2020, Neoplasia.

[21]  Shaoliang Zhu,et al.  Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis , 2020, Cancer Cell International.

[22]  J. Jia,et al.  miR-106a Regulates Cell Proliferation and Autophagy by Targeting LKB1 in HPV-16–Associated Cervical Cancer , 2020, Molecular Cancer Research.

[23]  Bin Liu,et al.  MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and chemo-resistance of gastric cancer , 2020, Cell Death & Disease.

[24]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[25]  Q. Cheng,et al.  LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p , 2020, Cell cycle.

[26]  C. Ohyama,et al.  Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy , 2020, International Urology and Nephrology.

[27]  M. Fan,et al.  Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer , 2020, Molecular therapy oncolytics.

[28]  Chuanzhao Zhang,et al.  LncRNA MAGI2‐AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR‐374b‐5p/SMG1 signaling pathway , 2019, Journal of cellular physiology.

[29]  Henry W. Long,et al.  ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. , 2019, Cancer cell.

[30]  Chawnshang Chang,et al.  LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex , 2019, Nucleic acids research.

[31]  Ximing J. Yang,et al.  Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression , 2018, The Journal of clinical investigation.

[32]  Qifeng Yang,et al.  LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215 , 2018, Journal of cellular physiology.

[33]  Yu Yang,et al.  Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression. , 2018, Biochemical and biophysical research communications.

[34]  Hong Zhang,et al.  LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway , 2018, Molecular cancer.

[35]  M. Hudson.  Human , 2018, Critical Theory and the Classical World.

[36]  Kui Liu,et al.  Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway , 2018, Human Cell.

[37]  Liuqing Yang,et al.  Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. , 2017, Trends in cell biology.

[38]  Wei-bo Xu,et al.  Long non-coding RNA PCAT-1 contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[39]  D. Pei,et al.  MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5 , 2017, Cell Death and Disease.

[40]  A. Bhan,et al.  Long Noncoding RNA and Cancer: A New Paradigm. , 2017, Cancer research.

[41]  Zendra Zehner,et al.  A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer , 2017, International Journal of Molecular Sciences.

[42]  Q. Mo,et al.  Twist1 Promotes Breast Cancer Invasion and Metastasis by Silencing Foxa1 Expression , 2016, Oncogene.

[43]  Y. Y. Lu,et al.  Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer. , 2016, Genetics and molecular research : GMR.

[44]  賢治 高橋,et al.  膵癌とlong non-coding RNA , 2016 .

[45]  Jindan Yu,et al.  Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer , 2015, Genes & diseases.

[46]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[47]  Andreas Heger,et al.  Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy , 2014, European urology.

[48]  L. Tabernero,et al.  Dual-specificity phosphatases as molecular targets for inhibition in human disease. , 2014, Antioxidants & redox signaling.

[49]  S. Cykert.  A New Paradigm. , 2014, Chest.

[50]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[51]  T. Blondal,et al.  Efficient identification of miRNAs for classification of tumor origin. , 2014, The Journal of molecular diagnostics : JMD.

[52]  Chenyu Zhang,et al.  Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer , 2013, Oncology letters.

[53]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[54]  Shih-Chieh Lin,et al.  Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. , 2011, The Journal of clinical investigation.

[55]  Klaus H. Kaestner,et al.  FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis , 2010, Development.

[56]  Massimo Negrini,et al.  Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.

[57]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[58]  Anindya Dutta,et al.  MicroRNAs in cancer. , 2009, Annual review of pathology.

[59]  C. Mackay,et al.  Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses , 2007, Nature Reviews Drug Discovery.

[60]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[61]  Yuxin Yin,et al.  PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression , 2003, Nature.

[62]  J. Hahn,et al.  Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. , 1999, Blood.

[63]  Kathleen Kelly,et al.  Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1 , 1994, Nature.